Cargando…

In-patient Tolvaptan use in SIADH: care audit, therapy observation and outcome analysis

BACKGROUND: Indications for use of tolvaptan in SIADH-associated hyponatraemia remain controversial. We audited our local guidelines for Tolvaptan use in this situation to review treatment implications including drug safety, hospital admission episode analysis (episodes of liver toxicity, CNS myelin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Humayun, Malik Asif, Cranston, Iain C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5674865/ https://www.ncbi.nlm.nih.gov/pubmed/29110656 http://dx.doi.org/10.1186/s12902-017-0214-2

Ejemplares similares

THU239 Tolvaptan For SIADH Management In Children
por: Igarashi, Mizuho, et al.
Publicado: (2023)

Tolvaptan use during hyperhydration in paediatric intracranial lymphoma with SIADH
por: Willemsen, Ruben H, et al.
Publicado: (2016)

Long-term low-dose tolvaptan efficacy and safety in SIADH
por: Bondanelli, Marta, et al.
Publicado: (2023)

SIADH-related hyponatremia in hospital day care units: clinical experience and management with tolvaptan
por: De las Peñas, Ramón, et al.
Publicado: (2015)

The diagnosis and management of inpatient hyponatraemia and SIADH
por: Grant, Paul, et al.
Publicado: (2015)

Tolvaptan Versus Fluid Restriction in the Treatment of Hyponatremia Resulting from SIADH Following Pituitary Surgery
por: Kleindienst, Andrea, et al.
Publicado: (2020)

Case Report: Long-Term Tolvaptan Treatment in a Child With SIADH and Suprasellar Arachnoid Cyst
por: Puma, Andrea, et al.
Publicado: (2021)

Comparison of tolvaptan treatment between patients with the SIADH and congestive heart failure: a single-center experience
por: Park, Gun Ha, et al.
Publicado: (2018)

A rapid and efficient way to manage hyponatremia in patients with SIADH and small cell lung cancer: treatment with tolvaptan
por: Petereit, Claudia, et al.
Publicado: (2013)

The role of tolvaptan in managing hyponatremia in small cell lung cancer patients with SIADH: a retrospective study of 23 cases
por: Ren, Peng, et al.
Publicado: (2021)

SIADH and hyponatraemia: foreword
por: O’Donoghue, Donal, et al.
Publicado: (2009)

Tolvaptan
por: Rangarajan, Bharath, et al.
Publicado: (2014)

SIADH Associated with Prostate Cancer
por: Lee, Kyun Sang, et al.
Publicado: (2007)

PSUN119 Obesity As An Independent Factor In Outcome Of SIADH Hospitalizations
por: Maghari, Ibrahim, et al.
Publicado: (2022)

SIADH and hyponatraemia: why does it matter?
por: Hoorn, Ewout J., et al.
Publicado: (2009)

Current and future treatment options in SIADH
por: Zietse, Robert, et al.
Publicado: (2009)

The clinical challenge of SIADH—three cases
por: van der Lubbe, Nils, et al.
Publicado: (2009)

Syndrome of inappropriate ADH secretion (SIADH) associated with citalopram use
por: Kirpekar, Vivek C., et al.
Publicado: (2005)

Tolvaptan should be used very carefully in very elderly patients
por: Kahraman, Fatih, et al.
Publicado: (2018)

Urea Use for SIADH: A Case Report and Review of the Literature
por: Flores, Monica, et al.
Publicado: (2021)

Three Synchronous Tumors Discovered in SIADH Investigation
por: Fonseca, Ricardo, et al.
Publicado: (2017)

Guillain–Barré syndrome hyponatremia: is it SIADH or pseudohyponatremia?
por: Zemke, Anna M, et al.
Publicado: (2018)

Hyponatremia in children with pneumonia rarely means SIADH
por: Tagarro, Alfredo, et al.
Publicado: (2018)

FRI356 SIADH In Acromegaly And Cerebrovascular Accident
por: Simrampreet, Gill, et al.
Publicado: (2023)

Idiopathic SIADH in young patients: don't forget the nose
por: Parrilla, C., et al.
Publicado: (2017)

Idiopathic SIADH in the premature newborn, a case report
por: van der Lee, D., et al.
Publicado: (2020)

Tolvaptan- and Tolvaptan-Metabolite-Responsive T Cells in Patients with Drug-Induced Liver Injury
por: Gibson, Andrew, et al.
Publicado: (2020)

Effectiveness of tolvaptan monotherapy and low-dose furosemide/tolvaptan combination therapy for hepatoprotection and diuresis in a rat cirrhotic model
por: Tanabe, Norikazu, et al.
Publicado: (2017)

Potential effect of tolvaptan on polycystic liver disease for patients with ADPKD meeting the Japanese criteria of tolvaptan use
por: Mizuno, Hiroki, et al.
Publicado: (2022)

Evidence for the use of demeclocycline in the treatment of hyponatraemia secondary to SIADH: a systematic review
por: Miell, J., et al.
Publicado: (2015)

Long-Term Vaptan Treatment of Idiopathic SIADH in an Octogenarian
por: Büttner, Stefan, et al.
Publicado: (2017)

Neuroblastoma in the Elderly and SIADH: Case Report and Review of the Literature
por: Pellegrino, Micaela, et al.
Publicado: (2012)

Hyponatraemia after Fracture Is Often Caused by Hypovolaemia, Not SIADH
por: Cumming, K., et al.
Publicado: (2015)

Be aware of the effects of glucocorticoids on SIADH: A case report
por: Li, Huaqian, et al.
Publicado: (2019)

MON-425 SIADH with Epistaxis: Rule out Esthesioneuroblastoma
por: Diamond, Samantha, et al.
Publicado: (2019)

Severe case of COVID −19 pneumonia complicated by SIADH
por: Fajri, Mohamed, et al.
Publicado: (2021)

Severe hyponatremia due to trimethoprim-sulfamethoxazole-induced SIADH
por: Marak, Creticus, et al.
Publicado: (2022)

PMON63 The Impact of Protein-Energy Malnutrition on Outcomes of Adult Hospitalizations for SIADH: A Nationwide Analysis
por: Ojemolon, Pius, et al.
Publicado: (2022)

RF32 | PSUN50 Hypertriglyceridemia as an Independent Risk Factor on Outcomes of Admissions for SIADH
por: Kwei-Nsoro, Robert, et al.
Publicado: (2022)

Tolvaptan, hyponatremia, and heart failure
por: Zmily, Hammam D, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_r1be2cplc8cbbd76lt6meiv0h8